TITUSVILLE - The Janssen Pharmaceutical Companies of
The data are being shared online as an accepted poster presentation (#P1004) during MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.
The study, which enrolled 200 U.S. patients with RMS measured multiple sclerosis (MS)-related fatigue and its impact on daily life using the Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS), a novel disease-specific scale developed using methods consistent with the
'At Janssen, we approach diseases holistically, considering both fundamental and secondary - or 'hidden' - symptoms that may affect the well-being of people living with neurodegenerative conditions, like MS,' said
Separately, Janssen, in partnership with the
More than 75 percent of patients agree it's difficult for others in their life to truly understand how fatigue impacts them.
Nearly 70 percent of respondents feel that they should hide their fatigue from others.
Over 40 percent of respondents reported feeling lonely as a result of their fatigue.
Approximately 37 percent stated they had trouble making new friends or had strained friendships because of fatigue.
Nearly half of patients take breaks throughout the day to manage their fatigue. In the workplace specifically, 85 percent reported their fatigue impacts how they feel and act at work.
More than one-third of respondents reported that they either arrived late or left work early, called in sick (from work) or missed family/social activities because of their fatigue.
More than 90 percent of patients have discussed their fatigue with their healthcare provider (HCP); however, 56 percent say they don't feel their HCP fully understands the overall impact fatigue has on their daily lives.
About Multiple Sclerosis (MS)
MS is a chronic autoimmune inflammatory disease of the central nervous system affecting 2.3 million people worldwide,i with females more impacted than males.ii The disease is characterized by demyelinationii and axonal loss leading to neurological impairment and severe disability.iii Relapsing forms of MS, which make up 85 percent of all MS cases, include clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS.iv In addition to the debilitating neurological symptoms of the disease, patients often also suffer from 'hidden symptoms,' namely fatigue and depression, both of which are major contributors to reduced quality of life.v Fatigue is one of the most common symptoms of MS, occurring in about 80 percent of patients.vi
Relapses are defined as new, worsening or recurrent neurological symptoms that last for more than 24 hours with the absence of fever or infections. Relapses may be fully resolved over days or weeks or lead to persistent residual deficits and accumulation of disability.vii
About the
The survey was conducted by
About the
The
We are more than an organization. We are a movement. United in our collective power to do something about MS now and end this disease forever. The gathering place for people with MS, their family and loved ones, healthcare providers, volunteers, donors, fundraisers, advocates, community leaders and all those that seek a world free of MS. A place to connect and take action. In order to change the world, we mobilize all possible human and financial resources to achieve results.
About the Janssen Pharmaceutical Companies of
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of
Cautions Concerning Forward-Looking Statements
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Contact:
Stela Meirelles
Tel: +1 (732) 258-1540
(C) 2020 Electronic News Publishing, source